Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oncor

This article was originally published in The Gray Sheet

Executive Summary

Gene-based cancer test firm is seeking additional funds for its North American operations via an equity financing, sale of non-strategic assets including its Research Products Division and interests in certain other affiliates, and "release of legal restrictions on the availability of certain cash deposits," the firm reports. Recently adopted cost-cutting measures include slicing its workforce by 40% in North America, which is anticipated to be completed by the end of the second quarter. A recent addition to an existing credit facility from a "major Oncor shareholder" brings available cash to approximately $3.2 mil. The Gaithersburg, Maryland firm is working with Lehman Brothers to "seek a major strategic transaction, including the possible sale of the company." The company disclosed in March plans to divest all non-oncology ventures in an effort to refocus the company ("The Gray Sheet" March 30, p. 26)

You may also be interested in...



Cambridge Vision Achieved, AstraZeneca Looks To Realize ‘Pipeline 2’ Ambitions

Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.

Pfizer/BioNTech’s Comirnaty Supply Agreements Unaffected Despite EU Green Light For Under-12s

Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.

Novo Nordisk Braced For China Insulin Scheme Impact

The value-based procurement scheme in China is about to be implemented on insulin products and while most of Novo Nordisk's therapies were included in the tender, price cuts are going to impact global sales growth by 3% next year.

UsernamePublicRestriction

Register

MT010026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel